Syntopix Group PLC
This article was originally published in Start Up
AIM-listed Syntopix group aims to leverage the antimicrobial expertise of its scientific founders at the University of Leeds to become a world-class drug development company providing clinical solutions for important dermatological diseases.
You may also be interested in...
Ever hungry for new investment opportunities, VCs are now backing start-ups developing novel dermatology products for both medical and cosmetic conditions. These aren't your typical "derm" companies. Not content to invent new delivery vectors for existing medicines or reformulate them into more patient friendly creams, these fledgling companies are trying to develop new chemical entities based on novel skin biology.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.